BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/26/2019 10:13:56 AM | Browse: 589 | Download: 1433
 |
Received |
|
2019-03-12 03:44 |
|
Peer-Review Started |
|
2019-03-15 01:57 |
|
To Make the First Decision |
|
2019-04-18 03:26 |
|
Return for Revision |
|
2019-04-19 06:25 |
|
Revised |
|
2019-05-02 13:20 |
|
Second Decision |
|
2019-05-22 09:45 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-05-23 12:58 |
|
Articles in Press |
|
2019-05-23 12:58 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-06-05 15:30 |
|
Typeset the Manuscript |
|
2019-07-22 02:46 |
|
Publish the Manuscript Online |
|
2019-07-26 10:13 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Prospective Study |
| Article Title |
Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: A cohort study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Maria C Rossi, Walter O Inojosa, Giuseppe Battistella, Antonella Carniato, Francesca Farina, Mario Giobbia and Pier G Scotton |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Walter O Inojosa, MD, Doctor, Doctor, Infectious Diseases Unit, Treviso Hospital, Piazza Ospedale 1, Treviso 31100, Italy. walteromar.inojosa@aulss2.veneto.it |
| Key Words |
Fixed-dose coformulations; Fixed dose coformulation regimens; Multitablet regimens; Human immunodeficiency virus; Highly active antiretroviral therapy; |
| Core Tip |
In a cohort of adults with suppressed human immunodeficiency virus-type 1 (HIV-1) viremia, the switch from fixed-dose coformulations to the corresponding multitablet regimens (MTRs) did not affect the effectiveness of antiretroviral therapy in terms of virological response and immunological recovery. Our data came from a well-established study population that was demographically representative of the Italian HIV-infected population, with very high levels of adherence and complete virological suppression. By involving patients in the decision to switch to a MTR for economic reasons, the magnitude of the potential clinical benefits from fixed dose coformulation regimens appears to be cancelled by the efficacy and tolerability of the antiretroviral drugs currently available in MTRs, even in a generic formulation, despite a small risk of drug discontinuation in patients who switched to MTRs because of mere convenience issues due to the number of tablets. |
| Publish Date |
2019-07-26 10:13 |
| Citation |
Rossi MC, Inojosa WO, Battistella G, Carniato A, Farina F, Giobbia M, Fuser R, Scotton PG. Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: A cohort study. World J Clin Cases 2019; 7(14): 1814-1824 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i14/1814.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i14.1814 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
